,NSG 533 Exam 3 Advanced Pharmacology Questions And Answers
2026/2027 Wilkes University
Q1. Why is inhaled corticosteroid-containing therapy used as a
foundation of long-term asthma treatment?
A) It directly relaxes bronchial smooth muscle within seconds
B) It suppresses chronic airway inflammation and reduces exacerbation risk
C) It permanently eliminates airway hyperresponsiveness
D) It blocks muscarinic receptors in the bronchial tree
Correct Answer: B) It suppresses chronic airway inflammation and reduces
exacerbation risk
Rationale: Inhaled corticosteroids reduce inflammatory-cell activity,
cytokine production, mucosal edema, and airway hyperresponsiveness.
Regular exposure decreases symptoms and, importantly, lowers the risk of
serious asthma exacerbations.
Q2. Formoterol can be used in an inhaled corticosteroid-formoterol
reliever regimen because formoterol has which property?
A) Irreversible beta-2 receptor binding
B) Strong anticholinergic activity
C) Long duration with delayed onset
D) Rapid bronchodilator onset despite being long acting
Correct Answer: D) Rapid bronchodilator onset despite being long acting
Rationale: Formoterol is a long-acting beta-2 agonist with sufficiently rapid
onset to provide symptom relief. When combined with an inhaled
corticosteroid, each reliever dose simultaneously treats bronchoconstriction
and delivers anti-inflammatory therapy.
Q3. Why should a long-acting beta-2 agonist generally not be used
as asthma monotherapy?
A) Bronchodilation without adequate anti-inflammatory treatment can
increase the risk of severe asthma outcomes
B) LABAs completely prevent inhaled corticosteroids from binding their
receptors
, C) LABAs cause immediate corticosteroid resistance
D) They have no bronchodilator activity in asthma
Correct Answer: A) Bronchodilation without adequate anti-inflammatory
treatment can increase the risk of severe asthma outcomes
Rationale: Asthma is fundamentally an inflammatory airway disorder. LABA
monotherapy can improve bronchoconstriction while leaving underlying
inflammation inadequately treated. LABAs are therefore paired with inhaled
corticosteroid therapy in asthma.
Q4. A patient has persistent asthma symptoms despite appropriate
use of a low-dose inhaled corticosteroid. Which addition most
directly provides sustained bronchodilation?
A) Oral antihistamine
B) Leukotriene synthesis stimulant
C) Long-acting beta-2 agonist
D) Proton pump inhibitor
Correct Answer: C) Long-acting beta-2 agonist
Rationale: A LABA provides prolonged beta-2 receptor stimulation and
bronchodilation. When symptoms remain inadequately controlled with
inhaled corticosteroid therapy, an ICS-LABA combination is a common
escalation strategy.
Q5. Albuterol relieves acute bronchospasm primarily through which
mechanism?
A) Blockade of leukotriene receptors
B) Stimulation of beta-2 adrenergic receptors in airway smooth muscle
C) Inhibition of IgE synthesis
D) Suppression of eosinophil production
Correct Answer: B) Stimulation of beta-2 adrenergic receptors in airway
smooth muscle
Rationale: Beta-2 receptor activation increases intracellular cyclic AMP in
bronchial smooth muscle, producing rapid relaxation and bronchodilation.
2026/2027 Wilkes University
Q1. Why is inhaled corticosteroid-containing therapy used as a
foundation of long-term asthma treatment?
A) It directly relaxes bronchial smooth muscle within seconds
B) It suppresses chronic airway inflammation and reduces exacerbation risk
C) It permanently eliminates airway hyperresponsiveness
D) It blocks muscarinic receptors in the bronchial tree
Correct Answer: B) It suppresses chronic airway inflammation and reduces
exacerbation risk
Rationale: Inhaled corticosteroids reduce inflammatory-cell activity,
cytokine production, mucosal edema, and airway hyperresponsiveness.
Regular exposure decreases symptoms and, importantly, lowers the risk of
serious asthma exacerbations.
Q2. Formoterol can be used in an inhaled corticosteroid-formoterol
reliever regimen because formoterol has which property?
A) Irreversible beta-2 receptor binding
B) Strong anticholinergic activity
C) Long duration with delayed onset
D) Rapid bronchodilator onset despite being long acting
Correct Answer: D) Rapid bronchodilator onset despite being long acting
Rationale: Formoterol is a long-acting beta-2 agonist with sufficiently rapid
onset to provide symptom relief. When combined with an inhaled
corticosteroid, each reliever dose simultaneously treats bronchoconstriction
and delivers anti-inflammatory therapy.
Q3. Why should a long-acting beta-2 agonist generally not be used
as asthma monotherapy?
A) Bronchodilation without adequate anti-inflammatory treatment can
increase the risk of severe asthma outcomes
B) LABAs completely prevent inhaled corticosteroids from binding their
receptors
, C) LABAs cause immediate corticosteroid resistance
D) They have no bronchodilator activity in asthma
Correct Answer: A) Bronchodilation without adequate anti-inflammatory
treatment can increase the risk of severe asthma outcomes
Rationale: Asthma is fundamentally an inflammatory airway disorder. LABA
monotherapy can improve bronchoconstriction while leaving underlying
inflammation inadequately treated. LABAs are therefore paired with inhaled
corticosteroid therapy in asthma.
Q4. A patient has persistent asthma symptoms despite appropriate
use of a low-dose inhaled corticosteroid. Which addition most
directly provides sustained bronchodilation?
A) Oral antihistamine
B) Leukotriene synthesis stimulant
C) Long-acting beta-2 agonist
D) Proton pump inhibitor
Correct Answer: C) Long-acting beta-2 agonist
Rationale: A LABA provides prolonged beta-2 receptor stimulation and
bronchodilation. When symptoms remain inadequately controlled with
inhaled corticosteroid therapy, an ICS-LABA combination is a common
escalation strategy.
Q5. Albuterol relieves acute bronchospasm primarily through which
mechanism?
A) Blockade of leukotriene receptors
B) Stimulation of beta-2 adrenergic receptors in airway smooth muscle
C) Inhibition of IgE synthesis
D) Suppression of eosinophil production
Correct Answer: B) Stimulation of beta-2 adrenergic receptors in airway
smooth muscle
Rationale: Beta-2 receptor activation increases intracellular cyclic AMP in
bronchial smooth muscle, producing rapid relaxation and bronchodilation.
